Open CFD account Free Demo
Call: +248 4 671 903 Mail: [email protected]
Log In Open Account
Log In Open Account
Log In Open Account
News & Analysis
Open Account
News & Analysis
Open Account

Bristol-Myers Squibb exceeds Q1 expectations

2 May 2022 By Klavs Valters

Share

US pharmaceutical company Bristol-Myers Squibb Co. reported first quarter financial results on Friday, beating analyst expectations.

The company reported revenue of $11.648 billion (up 5% year-over-year) vs. $11.349 billion expected.

Earnings per share reported at $1.96 per share (a 13% increase year-over-year) vs. $1.91 per share estimate.

”We continue to execute against our strategic priorities, deliver solid revenue and earnings growth and advance our product pipeline,” company CEO, Giovanni Caforio said on the results.

”Thanks to our team’s hard work and dedication, we achieved regulatory approvals of Opdualag and Camzyos, our new first-in-class medicines for patients living with metastatic melanoma and symptomatic obstructive hypertrophic cardiomyopathy, respectively. These milestone achievements, combined with our promising product pipeline and strong financial flexibility, provide a solid foundation that will enable us to deliver sustained growth and long-term benefits for our patients,” Caforio concluded.

Bristol-Myers Squibb Co. chart

The stock was down by 2.5% on Friday at $75.21 per share.

Here is how the stock has performed in the past year:

  • 1 Month +1.96%
  • 3 Month +96%
  • Year-to-date +72%
  • 1 Year +59%

Bristol-Myers Squibb price targets

  • Morgan Stanley: $64
  • Wells Fargo: $65
  • Goldman Sachs: $72
  • Barclays: $66

Bristol-Myers Squibb Co. is the 65th largest company in the world with a market cap of $160 billion.

You can trade Bristol-Myers Squibb Co. (BMY) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Bristol-Myers Squibb Co., TradingView, CompaniesMarketCap

The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs. These documents are available here.

#Economy #Economics #Finance #Markets